Advanced search
Publication Cover
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration Volume 24, 2023 - Issue 5-6
Submit an article Journal homepage
2,274
Views
0
CrossRef citations to date
0
Altmetric
ALS Untangled

ALSUntangled # 69: astaxanthin

Timothy Fullam1 Department of Neurology, UTSA, San Antonio, TX, USAView further author information
,
Carmel Armon2 Department of Neurology, Loma Linda University, Loma Linda, CA, USAView further author information
,
Paul Barkhaus3 Department of Neurology, Medical College of Wisconsin, Milwaukee, WI, USAView further author information
,
Benjamin Barnes4 Department of Neurology, Medical College of Georgia, Augusta, GA, USAView further author information
,
Morgan Beauchamp5 Neurosciences Clinical Trials Unit, UNC Chapel Hill, NC, USAView further author information
,
Michael Benatar6 Department of Neurology, University of Miami, Miami, FL, USAORCID Iconhttps://orcid.org/0000-0003-4241-5135View further author information
ORCID Icon,
Tulio Bertorini7 Neurology Department, University of Tennessee Health Science Center, Memphis, TN, USAView further author information
,
Robert Bowser8 Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USAORCID Iconhttps://orcid.org/0000-0001-5404-7259View further author information
ORCID Icon,
Mark Bromberg9 Department of Neurology, University of Utah, Salt Lake City, UT, USAView further author information
,
Javier Mascias Cadavid10 ALS Department, Hospital Carlos III-La Paz, Madrid, SpainView further author information
,
Gregory T. Carter11 Department of Rehabilitation, Elson S. Floyd College of Medicine, Washington State University, Spokane, WA, USAView further author information
,
Mazen Dimachkie12 Department of Neurology, University of Kansas, Kansas City, KS, USAView further author information
,
Dave Ennist13 Origent Data Sciences, Inc, Vienna, VA, USAView further author information
,
Eva L. Feldman14 Department of Neurology, University of Michigan, Ann Arbor, MI, USAView further author information
,
Terry Heiman-patterson15 Department of Neurology, Temple Health, Philadelphia, PA, USAView further author information
,
Sartaj Jhooty16 University of North Carolina at Chapel Hill, Chapel Hill, NC, USAView further author information
,
Isaac Lund17 Green Hope High School, Cary, NC, USAView further author information
,
Christopher Mcdermott18 Department of Neuroscience, University of Sheffield, Sheffield, UKORCID Iconhttps://orcid.org/0000-0002-1269-9053View further author information
ORCID Icon,
Gary Pattee19 Department of Neurology, University of Nebraska Medical Center, Omaha, NE, USAView further author information
,
Dylan Ratner20 Tulane University, New Orleans, LA, USAView further author information
,
Paul Wicks21 Independent Consultant, Lichfield, UK, andORCID Iconhttps://orcid.org/0000-0002-2293-9284View further author information
ORCID Icon &
Richard Bedlack22 Department of Neurology, Duke University, Durham, NC, USACorrespondence[email protected]
View further author information
 show all
Pages 553-557 | Received 29 Dec 2022, Accepted 16 Jan 2023, Published online: 24 Jan 2023
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days

Abstract

ALSUntangled reviews alternative and off-label treatments for people living with amyotrophic lateral sclerosis (PALS). Here we review astaxanthin which has plausible mechanisms for slowing ALS progression including antioxidant, anti-inflammatory, and anti-apoptotic effects. While there are no ALS-specific pre-clinical studies, one verified “ALS reversal” occurred in a person using a combination of alternative therapies which included astaxanthin. There have been no trials of astaxanthin in people living with ALS. Natural astaxanthin appears to be safe and inexpensive. Based on the above information, we support further pre-clinical and/or clinical trials of astaxanthin in disease models and PALS, respectively, to further elucidate efficacy.

Declaration of interest

Timothy Fullam reports no conflicts of interest. Richard Bedlack has research support from ALSA, Orion, MediciNova, and the Healey Center, and consulting support from AB Science, Alexion, ALSA, Amylyx, Biogen, Black Swan, Brainstorm Cell, Corcept, Cytokinetics, GenieUs, Guidepoint, ITF Pharma, Mallinkrodt, New Biotic, Orphazyme, Shinkei, and Woolsey Pharma.

Additional information

Funding

ALSUntangled is sponsored by the ALS Association.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Download PDF

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.